GeoVax Labs’ (GOVX) Buy Rating Reaffirmed at D. Boral Capital

D. Boral Capital reaffirmed their buy rating on shares of GeoVax Labs (NASDAQ:GOVX) in a report issued on Thursday morning,Benzinga reports. The brokerage currently has a $18.00 target price on the stock.

Several other equities research analysts have also recently weighed in on GOVX. HC Wainwright reaffirmed a “buy” rating and issued a $8.00 price target on shares of GeoVax Labs in a research report on Friday, November 15th. Alliance Global Partners started coverage on shares of GeoVax Labs in a research report on Monday, November 11th. They set a “buy” rating and a $15.00 target price for the company. Five equities research analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Buy” and an average target price of $14.20.

GeoVax Labs Stock Down 0.4 %

Shares of GOVX opened at $2.24 on Thursday. The company has a 50 day moving average price of $2.47 and a 200-day moving average price of $2.81. GeoVax Labs has a fifty-two week low of $1.09 and a fifty-two week high of $11.18.

GeoVax Labs (NASDAQ:GOVX) last announced its quarterly earnings results on Tuesday, November 12th. The company reported ($0.91) earnings per share for the quarter, topping the consensus estimate of ($1.29) by $0.38. The business had revenue of $2.79 million during the quarter, compared to analysts’ expectations of $1.84 million. During the same period in the previous year, the company posted ($4.80) EPS. As a group, sell-side analysts anticipate that GeoVax Labs will post -4.49 earnings per share for the current fiscal year.

Institutional Investors Weigh In On GeoVax Labs

An institutional investor recently bought a new position in GeoVax Labs stock. Virtu Financial LLC purchased a new stake in shares of GeoVax Labs, Inc. (NASDAQ:GOVX) during the third quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor purchased 40,210 shares of the company’s stock, valued at approximately $97,000. Virtu Financial LLC owned approximately 0.43% of GeoVax Labs at the end of the most recent quarter. 6.09% of the stock is owned by hedge funds and other institutional investors.

GeoVax Labs Company Profile

GeoVax Labs, Inc, a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and solid tumor cancers using modified vaccinia ankara virus-like particle vaccine platform. It is developing various preventive vaccines against (COVID-19), human immunodeficiency virus (HIV); Zika virus; malaria; and hemorrhagic fever viruses, such as Ebola, Sudan, Marburg, and Lassa, as well as therapeutic vaccines for HIV, chronic Hepatitis B infections, and solid tumor cancers.